Research programme: small molecule therapeutics - HUYA
Latest Information Update: 04 Nov 2017
At a glance
- Originator HUYA Bioscience International LLC; Organon
- Developer HUYA Bioscience International
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in China
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in USA
- 20 Oct 2009 Preclinical development is ongoing in USA and China